Starting with a timeline, the pathogenesis and defining the clinical syndrome of HLH #HLH#lymsm (1/8)
How to diagnose HLH? Soluble CD25 and ferritin are the most specific inflammatory markers (best ROC), so @ZorefAdi et al combined them into an 'optimised HLH inflammatory' (OHI) index, with an improved specificity for HLH
Next @ZorefAdi divides patients w malignancy-assoc HLH into those w inflammatory phenotypes (OHI+) versus those w/out, finding those w/out die mostly from underlying progressive disease whereas those w inflammation die mostly from multi-organ failure ashpublications.org/blood/article/… (6/8)
The paradox of HLH treatment: how to separate friend from foe?
"T-cell activation drives inflammation in familial HLH but it is essential for tumour surveillance. Or is this the 'dark side' of a hot 🔥 tumour microenvironment?" (7/8)
Conclusion & Tips:
- early CD25 & ferritin to ensure you have the right diagnosis
- hunt for underlying cause, make sure to do viral PCRs not just serologies
- consider pros and cons of timing of corticosteroids
We compiled infection rates across myeloma bispecific trials, updated to include #ASH22 data
The majority of patients across trials developed infections, w 20-45% developing grade 3 infections & some deaths from infection ⬇️
Note the frequency of neutropenia & hypogam
Of course, in single-arm trials, we cannot know whether these events are caused by the patients' multiply-relapsed myeloma (known to cause significant immunosuppression), previous lines of treatment, or trial drug/s, or the extent to which each factor contributes